Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Tarantino P, Tayob N, Villacampa G, Dang C, Yardley DA, Isakoff SJ, Valero V, Faggen M, Mulvey T, Bose R, Weckstein D, Wolff AC, Reeder-Hayes K, Rugo HS, Ramaswamy B, Zuckerman D, Hart L, Gadi VK, Constantine M, Cheng K, Garrett AM, Marcom PK, Albain K, DeFusco P, Tung N, Ardman B, Nanda R, Jankowitz RC, Rimawi M, Abramson V, Pohlmann PR, Van Poznak C, Forero-Torres A, Liu MC, Ruddy KJ, Waks AG, DeMeo M, Burstein HJ, Partridge AH, Dell'Orto P, Russo L, Krause E, Newhouse DJ, Kurt BB, Mittendorf EA, Schneider B, Prat A, Prat A, Winer EP, Krop IE, Tolaney SM, Consortium of the TBCRC Translational Investigators, TBCRC Translational Investigators.

Open source

DOI: 10.1200/jco.23.02170
Published: 2024-06-27
Container: J Clin Oncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.23.02170,
  title = {Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.},
  author = {Tarantino P and  Tayob N and  Villacampa G and  Dang C and  Yardley DA and  Isakoff SJ and  Valero V and  Faggen M and  Mulvey T and  Bose R and  Weckstein D and  Wolff AC and  Reeder-Hayes K and  Rugo HS and  Ramaswamy B and  Zuckerman D and  Hart L and  Gadi VK and  Constantine M and  Cheng K and  Garrett AM and  Marcom PK and  Albain K and  DeFusco P and  Tung N and  Ardman B and  Nanda R and  Jankowitz RC and  Rimawi M and  Abramson V and  Pohlmann PR and  Van Poznak C and  Forero-Torres A and  Liu MC and  Ruddy KJ and  Waks AG and  DeMeo M and  Burstein HJ and  Partridge AH and  Dell'Orto P and  Russo L and  Krause E and  Newhouse DJ and  Kurt BB and  Mittendorf EA and  Schneider B and  Prat A and  Prat A and  Winer EP and  Krop IE and  Tolaney SM and  Consortium of the TBCRC Translational Investigators and  TBCRC Translational Investigators.},
  year = {2024},
  journal = {J Clin Oncol},
  doi = {10.1200/jco.23.02170},
  url = {https://doi.org/10.1200/jco.23.02170}
}

RIS

TY  - JOUR
TI  - Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.
AU  - Tarantino P
AU  -  Tayob N
AU  -  Villacampa G
AU  -  Dang C
AU  -  Yardley DA
AU  -  Isakoff SJ
AU  -  Valero V
AU  -  Faggen M
AU  -  Mulvey T
AU  -  Bose R
AU  -  Weckstein D
AU  -  Wolff AC
AU  -  Reeder-Hayes K
AU  -  Rugo HS
AU  -  Ramaswamy B
AU  -  Zuckerman D
AU  -  Hart L
AU  -  Gadi VK
AU  -  Constantine M
AU  -  Cheng K
AU  -  Garrett AM
AU  -  Marcom PK
AU  -  Albain K
AU  -  DeFusco P
AU  -  Tung N
AU  -  Ardman B
AU  -  Nanda R
AU  -  Jankowitz RC
AU  -  Rimawi M
AU  -  Abramson V
AU  -  Pohlmann PR
AU  -  Van Poznak C
AU  -  Forero-Torres A
AU  -  Liu MC
AU  -  Ruddy KJ
AU  -  Waks AG
AU  -  DeMeo M
AU  -  Burstein HJ
AU  -  Partridge AH
AU  -  Dell'Orto P
AU  -  Russo L
AU  -  Krause E
AU  -  Newhouse DJ
AU  -  Kurt BB
AU  -  Mittendorf EA
AU  -  Schneider B
AU  -  Prat A
AU  -  Prat A
AU  -  Winer EP
AU  -  Krop IE
AU  -  Tolaney SM
AU  -  Consortium of the TBCRC Translational Investigators
AU  -  TBCRC Translational Investigators.
PY  - 2024
JO  - J Clin Oncol
DO  - 10.1200/jco.23.02170
UR  - https://doi.org/10.1200/jco.23.02170
ER  -

APA

P, T., N, T., G, V., C, D., DA, Y., SJ, I., V, V., M, F., T, M., R, B., D, W., AC, W., K, R., HS, R., B, R., D, Z., L, H., VK, G., M, C., K, C., AM, G., PK, M., K, A., P, D., N, T., B, A., R, N., RC, J., M, R., V, A., PR, P., C, V. P., A, F., MC, L., KJ, R., AG, W., M, D., HJ, B., AH, P., P, D., L, R., E, K., DJ, N., BB, K., EA, M., B, S., A, P., A, P., EP, W., IE, K., SM, T., Investigators, C. O. T. T. T., & Investigators., T. T. (2024). Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.. J Clin Oncol. https://doi.org/10.1200/jco.23.02170

Source records

europe-pmc · retrieved 2026-09-27T15:05:39.622Z